Complications and resource utilization in trauma patients with diabetes

Katherine He1*, Mark R. Hemmila2,3, Anne H. Cain-Nielsen2,3, David A. Machado-Aranda1, Lynn M. Frydrych2, Matthew J. Delano2

1 Department of Surgery, Brigham and Women’s Hospital, Boston, MA, United States of America, 2 Department of Surgery, Division of Acute Care Surgery, University of Michigan, Ann Arbor, MI, United States of America, 3 Michigan Trauma Quality Improvement Program, Ann Arbor, MI, United States of America

* Katherine.He@bwh.harvard.edu

Abstract

Diabetes is associated with poor outcomes in critically ill populations. The goal of this study was to determine if diabetic patients suffer poorer outcomes following trauma. Collaborative trauma patient data from 2012–2018 was analyzed. Patients with no signs-of-life, Injury Severity Score (ISS) <5, age <16 years, and hospitalization <1 day were excluded. Multivariable logistic and linear regression were used to compare patients with and without diabetes for selected outcomes. Risk-adjustment variables included demographics, physiology, comorbidities, and injury scoring. Of 106,141 trauma patients, 14,150 (13%) had diabetes. On admission, diabetes was associated with significantly increased risk of any, serious, infectious, urinary tract, sepsis, pneumonia, and cardiac complications. Diabetes was also associated with increased ventilator days (7.5 vs. 6.6 days, p = 0.003), intensive care unit days (5.8 vs. 5.3 days, p<0.001), and hospital length of stay (5.7 vs. 5.3 days, p<0.001). Subgroup analysis revealed the least injured diabetic category (ISS 5–15) suffered higher odds of hospital mortality and any, serious, infectious and cardiac complications. The association between diabetes, hospital mortality and complication rates in mild traumatic injury is independent of age. Trauma patients with diabetes experience higher rates of complications and resource utilization. The largest cohort of diabetics experience the least severe injuries and suffer the greatest in hospital mortality and complication rates. A better understanding of the physiologic derangements associated with diabetes is necessary to develop novel approaches to reduce excess trauma morbidity, mortality and resource consumption.

Background

With the growing ubiquity of the western diet and lifestyle, diabetes mellitus (DM) has become a common disease. Diabetes prevalence in the United States has almost tripled from 11.9 million people in 2000 to 30.3 million people in 2017, and the incidence has more than tripled from 1980–2017.[1]
Patients with DM are living longer and accumulating comorbidities that result in greater physiologic frailty. It has been well described that patients with complex comorbidities fare worse following traumatic injury.[2–4]. DM has been identified to be a leading global cause of years lived with disability (YLD) and in the United States is attributable to over 11% of deaths. [4,5]. This is surely an underestimate of the impact of DM, given one in four patients with DM is undiagnosed.[6] Dwindling healthcare dollars combined with increased DM morbidity will saddle an exhausted healthcare system and make attaining quality outcomes more challenging.

Trauma is a leading cause of death and nonfatal injury with almost 40 million emergency department visits annually in the United States[7]. The most recent data from the National Vital Statistics System at the Centers for Disease Control and Prevention National Center for Health Statistics report trauma as the #1 leading cause of death for the 1–44 year-old population and unintentional falls as the #1 leading cause of nonfatal injuries for all emergency department patients. The number of patients dying from traumatic injury and treated for unintentional falls has risen abruptly over the past decade, with over half of the increase attributable to patients over age 65.[8]

While several investigations have addressed the impact of hyperglycemia and glucose control on trauma outcomes,[9–12] there is a paucity of studies that address DM and its association with complications in traumatically injured patients. The studies that do examine the association between comorbid DM and trauma outcomes are limited in their ability to account for all confounders or outcomes.[13,14]

Given the increasing incidence, prevalence, and YLD of DM, the outcomes of trauma patients presenting with comorbid DM must be better characterized to more definitively demonstrate the contribution of DM to adverse trauma outcomes and resource utilization. The objective of this study is to use data from the Michigan Trauma Quality Improvement Program to examine the impact of DM on outcomes in trauma patients.

**Methods**

This project was approved by the University of Michigan Institutional Review Board. The data was initially collected for the purposes of Quality Improvement—this project is secondary use of these data. The data were fully anonymized and a waiver of informed consent was obtained.

**Michigan Trauma Quality Improvement Program (MTQIP)**

The Michigan Trauma Quality Improvement Program (MTQIP) is a statewide collaborative quality initiative that is sponsored by Blue Cross Blue Shield of Michigan/Blue Care Network (BCBSM/BCM) and includes 29 American College of Surgeons Committee on Trauma verified level 1 and 2 trauma centers. It receives over 19,000 case submissions per year and utilizes a data definitions manual that is updated annually and references existing national sources (National Surgical Quality Improvement Program, National Trauma Data Standard, Centers for Disease Control) when possible to achieve data consistency. The University of Michigan serves as the coordinating center for MTQIP.

**Data**

Data were abstracted from the MTQIP database for the years 2012–2018. Study inclusion criteria included age ≥16, primary mechanism of injury classified as blunt or penetrating, Injury Severity Scoring (ISS) ≥5, hospital admission ≥24 hours, and discharge disposition known. Patients with no signs of life when initially evaluated (systolic blood pressure = 0 mmHg, pulse = 0 bpm, Glasgow Coma Scale Score (GCS) = 3) and burn patients were excluded.[15,16] Due to the complexities of diagnosing type 1 versus type 2 DM, MTQIP data are unable to
differentiate the comorbid condition of DM by type. Patients were coded as diabetic if they self-reported DM, were on exogenous parenteral insulin or an oral hypoglycemic agent, or if they were previously diagnosed with DM per chart documentation.

**Analysis**

The primary outcome of interest was complication rates in patients with and without DM. Complication groupings analyzed included infection (incisional surgical site infection (SSI), organ space SSI, urinary tract infection (UTI), pneumonia, clostridium difficile infection, sepsis), cardiac (cardiac arrest requiring cardiopulmonary resuscitation—CPR, myocardial infarction—MI), renal (acute renal failure requiring dialysis—ARF), venous thromboembolism (VTE) (pulmonary embolism, deep vein thrombosis), and other (wound disruption, abdominal fascia left open, acute respiratory distress syndrome—ARDS, unplanned intubation, stroke/cerebral vascular accident, abdominal compartment syndrome—ACS, extremity compartment syndrome, decubitus ulcer, enterocutaneous fistula).

Complication rates for any complication, infectious complication, cardiac complication, acute renal failure, and VTE were compared between patients with and without DM using univariate methods (Pearson chi squared analysis and T-tests) with significance $p \leq 0.05$. Multivariable logistic regression analysis was then used to compare complication rates for patients with and without DM for the same above complications with the addition of severe complications (ARDS, pneumonia, unplanned intubation, VTE, ARF, stroke, cardiac arrest requiring CPR, MI, sepsis, ACS, extremity compartment syndrome, decubitus ulcer, enterocutaneous fistula). Infectious complications were further separated into SSI, UTI, clostridium difficile infection, sepsis, and pneumonia. We then performed multivariable logistic regression analysis for the subset of patients age $\geq 65$ to evaluate age as a predictor of outcome. Multivariable linear regression was then performed to compare average predicted ventilator-days, intensive care unit (ICU) days, and length of stay for patients with and without DM. Risk-adjustment variables included demographics (age, sex, race, transfer, blunt vs. penetrating trauma, history of smoking), physiology (GCS motor, Emergency Department (ED) pulse, ED blood pressure, abdominal fascia left open), comorbidities (DM, obesity, hypertension, dialysis dependence, drug use, history of cirrhosis, congestive heart failure, routine steroid use, peripheral vascular disease, metastatic cancer, active chemotherapy, ascites, history of psychiatric illness, actively anticoagulated), and injury scoring (ISS, Abbreviated Injury Score (AIS) $\geq 3$ in head/neck, face, chest, abdomen, extremity). Statistical analyses were performed using SAS software (version 9.3, Cary, NC).

**Results**

**Demographics**

The final analysis included 106,141 patients. Baseline patient demographics are presented in Table 1. Patients with DM were significantly older, more likely to be white, and more likely to be female. DM patients were significantly more likely to experience comorbid congestive heart failure, peripheral vascular disease, hypertension, cirrhosis, obesity, and be dependent on dialysis.

**Complication rates**

Complication rates and risk adjusted odds ratios of complications of patients with and without DM are presented in Table 2 and Table 3. Patients with DM were significantly more likely to experience any complication. They had significantly higher rates of infection, renal
complications, and cardiac complications. Rates of VTE between DM and non-DM patients showed no significant difference. There was no significant in-hospital mortality difference. Diabetic trauma patients had significantly higher odds of developing any complication, a severe complication, any infection, any renal complication, and any cardiac complication during their hospitalization (OR range 1.21–1.61). Of the infectious complications, diabetic trauma patients had significantly increased odds of developing UTIs, sepsis, and pneumonia (OR range 1.21–1.45). Overall, DM patients had significantly higher odds of complications and in particular, were significantly more likely to develop infections including UTI, sepsis, and pneumonia.

Table 1. Patient demographics.

|                   | No DM   | DM      | p-value |
|-------------------|---------|---------|---------|
|                   | (n = 91,991) | (n = 14,150) |         |
| Age               | 54.1 ± 23.2 | 69.6 ± 14.9 | <0.001  |
| Male              | 61.2%   | 55.5%   | <0.001  |
| ISS               | 12.3 ± 8.4 | 11.6 ± 6.9 | <0.001  |
| Race (Non-White)  | 25.2%   | 19.0%   | <0.001  |
| Congestive heart failure | 2.5%      | 8.1%     | <0.001  |
| PVD               | 0.7%    | 2.2%    | <0.001  |
| Hypertension      | 31.4%   | 75.3%   | <0.001  |
| Dialysis          | 0.7%    | 3.8%    | <0.001  |
| Cirrhosis         | 0.6%    | 1.3%    | <0.001  |
| Metastasis        | 0.4%    | 0.6%    | <0.001  |
| Active chemotherapy| 0.3%     | 0.6%     | <0.001  |
| Obesity           | 6.3%    | 12.0%   | <0.001  |
| Ascites           | 0.03%   | 0.09%   | <0.001  |
| Drug use          | 15.0%   | 5.0%    | <0.001  |
| Smoker            | 28.1%   | 14.7%   | <0.001  |
| Psychiatric history| 16.0%   | 18.5%   | <0.001  |
| Anticoagulated    | 10.3%   | 26.9%   | <0.001  |
| Blunt mechanism   | 91.7%   | 98.0%   | <0.001  |
| Transfer          | 18.0%   | 19.7%   | <0.001  |

ISS = injury severity score. PVD = peripheral vascular disease. DM = diabetes mellitus.

Table 2. Complication rates of patients with and without DM.

|                  | No Diabetes   | Diabetes   | p-value |
|------------------|---------------|------------|---------|
|                  | (n = 91,991)  | (n = 14,150)|         |
| Complications (Any) | 7.5%    | 9.7%  | <0.001  |
| Mortality         | 4.6%    | 4.9%  | 0.09    |
| Infection         | 4.4%    | 5.1%  | <0.001  |
| Cardiac           | 1.3%    | 1.9%  | <0.001  |
| Acute Renal Failure| 0.4%    | 0.8%  | <0.001  |
| VTE               | 1.3%    | 1.3%  | 0.9     |

DM = diabetes mellitus. VTE = venous thromboembolism. DM = diabetes mellitus.
Interestingly, trends in increased complication risk in diabetic patients were primarily found in the subset of patients with the lowest Injury Severity Scale rating 5–15 in Table 4. Diabetic patients in this category had increased odds of all complication groupings, including death, any complication, serious complication, infection, and cardiac complication. For patients with ISS 16–24, diabetic patients were only at a greater odds of developing infectious complication (OR 1.25). Patients with ISS 25–35 had greater odds of developing any, serious, and cardiac complications (OR range 1.22–1.66).

Hospital length of stay (HLOS), ICU length of stay (ILOS), and ventilator-days

Adjusted effect of DM on length of stay and ventilator-days are presented in Table 5. 38% of DM patients and 37% of non-DM patients were admitted to the ICU (p-value = 0.23). 14% of DM patients and 13% of non-DM patients were mechanically ventilated (p-value = <0.001). Trauma patients with DM experienced a significantly longer ILOS (5.8 vs. 5.3 days, p<0.001), HLOS (5.7 vs. 5.3 days, p<0.001), and a greater number of ventilator-days (7.5 vs. 6.6 days, p = 0.003). Diabetic patients remained on the ventilator, stayed in the ICU, and stayed in the hospital longer than their counterparts without DM, indicating greater health system resource consumption than their non-diabetic counterparts.

Complication rates, age ≥65

Complication rates of patients ≥65 years old with and without DM are presented in Table 6. As compared to our entire patient sample, patients ≥65 with DM were likewise significantly more likely to suffer any complication, a severe complication, renal failure, a cardiac complication, or any infection (OR range 1.26–1.28). The infectious complications patients ≥65 with DM were significantly more likely to experience than their non-DM peers were sepsis and pneumonia. Overall, our subset of patients ≥65 with DM did not experience more complications than patients with DM in the entire study population. Although DM patients tend to be
older, their increased risk of trauma complications is not due to the aging process but rather associated with the presence of DM.

### Full regression results and diagnostics

Full model specifications and results for all adjusted results (Tables 1, 3, 4, 5 and 6) are presented in [S1 Appendix](https://doi.org/10.1371/journal.pone.0221414). Variance inflation factors (VIFs) to assess collinearity are also shown in [S1 Appendix](https://doi.org/10.1371/journal.pone.0221414).

### Discussion

With the elderly, obese and diabetic populations expanding and populating our trauma centers, it is imperative that we understand the complications they are at risk for during hospitalization. Current literature clearly associates hyperglycemia with adverse outcomes in trauma and critical illness. However, DM has profound physiologic impacts in addition to hyperglycemia and contributes to immune suppression, physiologic frailty, and immune senescence which are all linked to poor outcomes. In this study, we report that trauma patients who are admitted with DM suffer an increased number and severity of complications, infections, and a greater number of ventilator-days and ILOS than those without DM. Most importantly, we have demonstrated that the largest DM group sustains the least severe trauma injuries (ISS 5–15) yet suffers higher odds of hospital mortality and complication rates compared with...

### Table 4. Outcomes for diabetic vs non-diabetic patients, stratified by ISS category.

|                  | ISS 5–15 | ISS 16–24 | ISS 25–35 | ISS >35 |
|------------------|----------|-----------|-----------|---------|
|                  | n = 80289| n = 16097 | n = 7742  | n = 2013|
| Mortality        | 1.25 (1.06, 1.48)* | 1.02 (0.80, 1.30) | 1.08 (0.87, 1.32) | 1.01 (0.56, 1.81) |
| Complications (Any) | 1.37 (1.26, 1.48)* | 1.13 (0.99, 1.29) | 1.22 (1.01, 1.48)* | 1.15 (0.78, 1.70) |
| Complications (Serious) | 1.38 (1.28, 1.49)* | 1.13 (0.99, 1.29) | 1.30 (1.07, 1.59)* | 1.14 (0.76, 1.71) |
| Infection        | 1.32 (1.18, 1.48)* | 1.25 (1.10, 1.44)* | 1.13 (0.90, 1.42) | 1.25 (0.85, 1.85) |
| Cardiac          | 1.43 (1.14, 1.79)* | 1.33 (0.94, 1.89) | 1.66 (1.20, 2.29)* | 1.07 (0.60, 1.88) |

ISS = injury severity score.
* Indicates statistically significant with p-value <0.05.

https://doi.org/10.1371/journal.pone.0221414.t004

### Table 5. Hospital days, ICU days, and ventilator-days of patients with and without DM.

|                  | No DM (n = 91,991) | DM (n = 14,150) | p-value |
|------------------|--------------------|-----------------|---------|
| Mechanical Ventilation, % | 12.9               | 13.7            | <0.001  |
| Admitted to ICU, %    | 37.0               | 37.7            | 0.23    |
| Ventilator-Days*     | 6.55 ± 0.27        | 7.50 ± 0.40     | 0.003   |
| ICU Days†            | 5.25 ± 0.21        | 5.78 ± 0.27     | <0.001  |
| Length of Stay‡      | 5.34 ± 0.17        | 5.69 ± 0.18     | <0.001  |

ICU = intensive care unit. DM = DM mellitus.
* Average predicted, for patients with >0 ventilator-days
† Average predicted, for patients with >0 ICU days
‡ Average predicted

https://doi.org/10.1371/journal.pone.0221414.t005
those in more severe injury categories. Lastly, we show that those who suffer from traumatic insults and have DM require more hospital resources to provide adequate care.

The association of hyperglycemia with adverse outcomes in the critically ill population is not novel.[17] Laird and colleagues performed a retrospective study of 516 ICU patients showing early stress hyperglycemia in critically ill patients leads to increased infection and mortality.[9] Bochicchio and coauthors examined prospective data on 942 trauma patients admitted to the ICU and found persistent hyperglycemia contributed to greater ILOS, HLOS, ventilator-days, infection rate, and mortality.[10] Chin performed a prospective study of 2,231 acutely injured patients and found tight glucose control to be associated with lower mortality and adverse outcomes.[11] However, these studies were designed to examine stress hyperglycemia and excluded patients with DM. While Yendamuri included DM patients in their study of 738 trauma patients showing admission hyperglycemia was associated with increased ILOS, HLOS, infectious morbidity, and mortality, the study did not separate diabetic from non-diabetic patients, precluding meaningful conclusions regarding the impact of DM on trauma outcomes.[12]

More recent studies have examined the association of comorbid DM and trauma outcomes but have not accounted for all confounders or outcomes. Kao examined 343,250 patients from the National Trauma Data Bank and showed DM was a weak risk factor for infectious morbidity and ILOS. However, their analysis was limited by inconsistent reporting of comorbidities between institutions and they did not examine the impact of DM on specific infectious complications.[13] Ahmad performed a retrospective analysis of 24,9778 matched trauma patients with and without DM and found greater ILOS, ventilator-days, and complications in patients with DM.[14] While their data was matched by age, sex, and ISS, many other unidentified factors could have contributed to differences in outcome, including dialysis, mechanism of injury, and smoking status.

Our study’s findings build upon previous reports, which have likewise found DM to be associated with increased ICU length of stay[13,14] and 1-2-day increase in ventilator-days. [14] While our data show an increased average predicted total length of stay (TLOS), literature has been inconsistent, in one case associating DM with a longer TLOS,[13] and in another case showing no difference in TLOS between patients with and without DM. In all studies,

| Complication (Any) | OR for DM | [95% CI for OR] | p-value |
|-------------------|-----------|----------------|--------|
| DM                | 1.26      | [1.14, 1.37]   | <0.001 |
| Complications (Severe) | 1.26       | [1.14, 1.39]   | <0.001 |
| Mortality         | 1.08      | [0.95, 1.24]   | 0.24   |
| Infection         | 1.28      | [1.13, 1.45]   | <0.001 |
| SSI               | 1.67      | [0.84, 3.33]   | 0.15   |
| UTI               | 1.15      | [0.99, 1.34]   | 0.07   |
| Cdiff             | 1.15      | [0.74, 1.78]   | 0.5    |
| Sepsis            | 1.69      | [1.22, 2.32]   | 0.001  |
| Pneumonia         | 1.26      | [1.07, 1.48]   | 0.006  |
| Cardiac           | 1.27      | [1.06, 1.48]   | 0.008  |
| Acute Renal Failure | 1.70     | [1.28, 2.25]   | <0.001 |
| VTE               | 1.12      | [0.86, 1.44]   | 0.4    |

SSI = surgical site infection. UTI = urinary tract infection. Cdiff = Clostridium difficile infection. VTE = venous thromboembolism. DM = DM mellitus. OR = odds ratio. CI = confidence interval.

https://doi.org/10.1371/journal.pone.0221414.t006
DM and hyperglycemia have been associated with significantly increased odds of multiple infectious complications.[9,12–14] Consistent with our results, DM has further been found to significantly increase a patient’s odds of developing infections like sepsis, UTI, wound infection, pneumonia, and decubitus ulcers.[14] However, our study uniquely examined the association of DM with severe complications including ARDS, pneumonia, unplanned intubation, VTE, ARF, stroke, cardiac arrest requiring CPR, MI, sepsis, ACS, extremity compartment syndrome, decubitus ulcer, and enterocutaneous fistula.

It is evident that DM patients require more healthcare resources than their non-diabetic counterparts and that DM has a substantial impact on the healthcare economy. The American DM Association performed a prevalence-based cost study in 2012 and found patients with DM spent 2.3 times more on medical expenditures than non-diabetic patients.[18] Their estimated total cost of diagnosed DM in 2012 was $245 billion, which included $176 billion in direct medical costs and $69 billion in reduced productivity. Inpatient hospital care comprised 43% of medical costs and was the largest burden of medical expenditures. These statistics are unsurprising, given our findings associating DM with poorer trauma outcomes.

Our finding that statistical increased mortality in diabetic patients was only found in mildly injured patients (ISS < 15) warrants additional attention. In our study, DM patients with severe injury defined as ISS > 15 had no statistically significant differences in mortality as compared to their non-diabetic counterparts. Increased odds for any, severe, and cardiac complications were significant in ISS 25–35 diabetic patients, however we were unable to evaluate clear patterns in mortality in patients with ISS > 15 due to lower prevalence of ISS > 15 injury as compared to ISS 5–15 injury (25,852 with ISS > 15 vs. 80,289 with ISS ≤ 15). Other studies have included ISS in their analyses but have matched by ISS[14] or used ISS as a continuous rather than categorical variable [13], which overlooks the non-linear relationship between ISS and outcomes. Future studies are necessary to determine if differences in mortality between non-diabetic and DM patients are consistent between severely injured (ISS > 15) and non-severely injured patients.

The negative impact of increased ventilator-days as seen in DM patients in our study is clear. In previous studies, increased ventilator-days has been shown to be associated with increased ventilator-associated pneumonia (VAP), increased costs,[19,20] longer ICU stay, and increased mortality.[21,22] Arthur 2016’s review of 12 studies with 3,571 participants found the estimated attributable mortality of VAP to be 13%. Cook 1998 and Arthur 2016 found that 10–20% of patients who are mechanically ventilated for greater than 24 hours developed VAP.[22,23] According to 2016 Infectious Diseases Society of America and the American Thoracic Society clinical guidelines, empiric antibiotic treatment for VAP necessitates broad-spectrum antibiotic coverage for *Pseudomonas aeruginosa*, other gram-negative bacilli, and often methicillin resistant *S. aureus*, depending on local antimicrobial resistant rates.[24] Empiric antibiotic regimens are not free from harm—rates of superinfection on empiric antibiotic coverage have been found to be up to 21% and adverse effects as high as 49%, depending on the choice of antibiotic.[22] Not only are DM patients more intrinsically susceptible to infection, they are also more likely to experience prolonged ventilator courses in comparison to their non-DM peers, and thus more likely to contract VAP and be exposed to the adverse drugs effects of broad-spectrum antibiotics.

Several reports have examined the connection between increased infectious morbidity and DM and have hypothesized that diabetic patients are predisposed to infection due to impaired neutrophil function, decreased adaptive immune response, and dysfunctional immune cell function through high serum levels of inflammatory mediators.[25,26] DM patients are also associated with bacterial pathogens with increased antibiotic resistance such as MRSA, *Pseudomonas*, and *Acinetobacter*, which are associated with ICU-related mortality.[27] Several of
these effects are exacerbated by the hyperglycemia seen in poorly controlled diabetic patients [25] and improved with insulin administration.[26,28] Surgical ICU patients randomized to intensive insulin therapy in Van den Berghe’s study of 1,548 patients experienced a significant decrease in hospital mortality of 32%.[29] Of note, this reduction in mortality was not found in the medical ICU.[29,30] Further research is warranted on other immunomodulatory interventions to address the immune perturbations caused by DM.

There are several limitations associated with working with a large database like the MTQIP database. The MTQIP is a prospectively collected and retrospectively analyzed dataset. The diagnosis of DM in our case was broad-based and not predicated on the American Diabetes Association diagnosis criteria. Patients were coded as diabetic by self-report, exogenous parenteral insulin or oral hypoglycemic agent use, or by previous DM diagnosis per chart documentation. The MTQIP database was unable to distinguish between patients with Type 1 and Type 2 DM and did not have data on length of diabetic history, which are significant factors in development of DM-related complications. As the incidence of DM in our study is 13%, slightly higher than the 9% DM population-based incidence nationwide,[6] we can reasonably infer that the vast majority, over 90%, of our study patients have Type II DM and not Type I DM. In-hospital glycemic data was not available, and as such, we were unable to compare outcomes between DM/non-DM patients and hyperglycemic/euglycemic patients. Additionally, due to the nature of the data collected, we were unable to comment on the rate of new diagnosis of DM in our cohort, which would be informative given the tendency of trauma for unmasking undiagnosed DM. Finally, our dataset included in-hospital mortality only. Due to the low frequency of death and short overall hospital stay in our cohort, we only unable to detect a difference in mortality between diabetic and non-diabetic patients in mildly injured patients with ISS <15. Further studies are warranted to investigate mortality trends in diabetic patients suffering trauma.

Future directions of study include evaluating outcomes in DM populations undergoing acute surgery, separating the impact of DM from hyperglycemia, and examining differences in outcomes between Type 1 and Type 2 DM or between insulin-dependent DM and non-insulin-dependent DM. Further studies warrant investigating proactive infection prevention strategies such as immune modulatory therapy or prophylactic antibiotic therapy in DM cohorts.[31,32] With continued improvements in biomarker technology, cellular function determination and host/pathogen genomic interaction modeling, strategically-engineered combinations of immune modulators could be deployed based on patient comorbidity profiles, immune function, and recovery course. There is a tremendous need to elucidate the cellular interactions between DM and the immunologic system that predispose DM patients to infectious morbidity and to develop pharmacologic interventions to decrease DM patients’ risk of infection, recidivism, healthcare cost, and death.

**Conclusions**

We found DM to be an independent risk factor for adverse outcomes in trauma including infection, sepsis, cardiac complications, acute renal failure, ventilator-days, ICU days, and total length of stay. In subgroup analysis, these trends were primarily seen in non-severely injured patients with ISS <16 and ISS 25–35. Notably, increased mortality in diabetic patients was only seen in ISS<15 patients. As DM rates increase worldwide, the trauma patient population will become increasingly co-morbidly challenged, physiologically frail, and susceptible to infectious morbidity with bacteria that are progressively resistant to conventional infection management. A better understanding of the physiologic pathways affecting immunologic
systems in DM trauma patients is vital to developing non-pharmacologic and pharmacologic interventions to decrease infectious morbidity and mortality in DM patients.

Supporting information
S1 Appendix. Full analyses.
(DOCX)

Acknowledgments
MJD would like to acknowledge the 2017 American Surgical Association Foundation Fellowship Research Award, the 2016 Shock Society Faculty Research Award, and the 2015 American Association for the Surgery of Trauma Research and Education Foundation Scholarship that supported this work.

LMF would like to acknowledge T32 HL007517, which supported this work.

MRH and AHCN were supported by the Michigan Trauma Quality Improvement Program (MTQIP) supported by Blue Cross Blue Shield of Michigan/Blue Care Network, a non-profit mutual corporation.

We would also like to acknowledge the following participants for their care of the trauma patients and submission of data to MTQIP:

James Wagner, Cara Seguin, Tracey Stockinger, Gail Colton, and Sharon Morgan, of Beaumont Dearborn; Michael Rebock, Barb Smith, Catherine Levinson, Robin Lebeis, Shauna DiPasquo, of Beaumont Farmington Hills; Randy Janczyk, Michelle Schnedler, Shannon O’Brien Zientek, Desiree Sisco, of Beaumont Royal Oak; Allan Lamb, Kathy Franzen, Ramona Dinu, Heather Payton, of Beaumont Trenton; Tom Rois, Sally Ossewaarde, Katie Sparks, and Jodie Vining, of Borgess Health; Oreste Romeo, Patricia Benoit, Tonya King-Stratton, Mary Loney, Dominique Termaat, of Bronson Methodist Hospital; Suja Patel, Deb Falkenberg, Kenda Parker, Deanne Krajkowski, and Kristin Wolfgang, of Covenant HealthCare; Anna Ledgerwood, Maidei Munemo, Katherine Dhue, and Greta Egger, of Detroit Receiving Hospital; Brian Shapiro, Zachary Landers, Jennifer Sunderman, and Raquel Yapchai, of Genesys Health System; Pat Patton, Jerry Stassinopulos, Beth Fasbinder, Velma Cuevas, and Cheryl Church, of Henry Ford Hospital; Scott Barnes, Chris McEachin, Rachel Kramer, Michelle Schwab, and Rose Morrison, of Henry Ford Macom Hospital; Leo Mercer, Michelle Maxson, Gloria Lahoud, Amber Dombrowski, and Shirley Ulmer, of Hurley Medical Center; Nick Nunnally, Ashley Brown, Alisha Sholtis, and Erin Veit, of McLaren Lapeer Hospital; Mandip Atwal, Sue Schafer, Marita Vandenber, April Pizzo, and Leslie Frezza, of McLaren Macom Hospital; John Ketner, Courtney Berry, Megan Wright, and Carolyn Ivan, of McLaren Oakland Hospital; Wayne VanderKolk, Sherri Veurink-Balicki, Kristi Diephouse, and Coleen Kelly, of Mercy Health St Marys; Thomas Veverka, Shari Meredith, Michelle Abedrabbo, and Lori Coppola, of MidMichigan Midland; Walt Noble, Shamariie Regenold, Tanya Jenkins, Jill Jean, and Allen Stout, of Munson Medical Center; Peter Lopez, Joann Burrington, Rebecca Steele, Carly Callahan, and LaToya Kimbrough, of Providence Hospital; Michael White, Gwyn Navas, Thomas Derkowski, Danielle Finn, Patty Danhoff, and TiJuan Davis, of Sinai Grace Hospital; John Kepros, Penny Stevens, Cynthia Harakas, Kristen Jorae, and Marie Maier, of Sparrow Hospital; Gaby Iskander, Amy Koestner, Kathy Crystal, Jennifer Haverkamp, Kristen Thornton, Gayle Mack, Melissa Moutrie, and Kelly Burns, of Spectrum Health; Joseph Buck, Karrie Brown, Melissa Cunningham, Marie Westfall, Melissa Jeffrey, and Kathleen Waderlow, of St John Hospital; Mary-Margaret Brandt, Wendy Wahl, Kathy Kempf, Donna Tommelein, Rebecca Peterson, and Nancy Hofman, of St Joseph Mercy Hospital Ann Arbor; Alicia
Kieninger, Carol Spinweber, Michele Hunt, and Ellen Noone-Eustice, of St Joseph Mercy Hospital Oakland; Samer Kais, Kerri Chernauckas, Kelly Bourdow, Erin Perdue, and Nancy Walter, of St Marys of Michigan; Lena Napolitano, Chris Wagner, Cindy Wegryn, Sara Samborn, Cece Roiter, and Diane Tuttle-Smith, of University of Michigan; Larry Lewis, Tammy Luoma, Sarah Sutter, and Lisa Taylor, of UP Health System Marquette.

**Author Contributions**

**Conceptualization:** Mark R. Hemmila, David A. Machado-Aranda, Lynn M. Frydrych, Matthew J. Delano.

**Data curation:** Anne H. Cain-Nielsen.

**Formal analysis:** Anne H. Cain-Nielsen.

**Investigation:** Mark R. Hemmila.

**Methodology:** Mark R. Hemmila, David A. Machado-Aranda, Matthew J. Delano.

**Software:** Anne H. Cain-Nielsen.

**Supervision:** Lynn M. Frydrych, Matthew J. Delano.

**Validation:** Matthew J. Delano.

**Writing – original draft:** Katherine He, Matthew J. Delano.

**Writing – review & editing:** Katherine He, Lynn M. Frydrych, Matthew J. Delano.

**References**

1. National Diabetes Statistics Report, 2017 n.d.:20.

2. CDC—Number of Adults—Diagnosed Diabetes—Data & Trends—Diabetes DDT n.d. http://www.cdc.gov/diabetes/statistics/prev/national/adults.htm (accessed November 27, 2016).

3. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet Lond Engl 2016; 387:1513–30. https://doi.org/10.1016/S0140-6736(16)00618-8 PMID: 27061877

4. Stokes A, Preston SH. Deaths Attributable to Diabetes in the United States: Comparison of Data Sources and Estimation Approaches. PLoS One 2017; 12:e0170219. https://doi.org/10.1371/journal.pone.0170219 PMID: 28121997

5. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet Lond Engl 2012; 380:2163–96. https://doi.org/10.1016/S0140-6736(12)61729-2 PMID: 23245607

6. Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014. Atlanta, GA: U.S. Department of Health and Human Services; 2014.

7. National Hospital Ambulatory Medical Care Survey: 2015 Emergency Department Summary Tables 2015:34.

8. Ten Leading Causes of Death and Injury—PDFs|Injury Center|CDC n.d. http://www.cdc.gov/injury/wisqars/leadingcauses.html (accessed November 27, 2016).

9. Laird AM, Miller PR, Kligo PD, Meredith JW, Chang MC. Relationship of early hyperglycemia to mortality in trauma patients. J Trauma 2004; 56:1058–62. https://doi.org/10.1097/01.TA.0000123267.39011.9f PMID: 15179246

10. Bochicchio GV, Sung J, Joshi M, Bochicchio K, Johnson SB, Meyer W, et al. Persistent hyperglycemia is predictive of outcome in critically ill trauma patients. J Trauma 2005; 58:921–4. https://doi.org/10.1097/01.TA.0000162141.26392.07 PMID: 15920404

11. Chin TL, Sauaia A, Moore EE, Chandler JG, Harr JN, Johnson JL, et al. Elderly patients may benefit from tight glucose control. Surgery 2012; 152:315–21. https://doi.org/10.1016/j.surg.2012.06.015 PMID: 22938893
12. Yendamuri S, Fulda GJ, Tinkoff GH. Admission hyperglycemia as a prognostic indicator in trauma. J Trauma 2003; 55:33–8. https://doi.org/10.1097/01.TA.0000074434.39928.72 PMID: 12855878

13. Kao LS, Todd SR, Moore FA. The impact of diabetes on outcome in traumatically injured patients: an analysis of the National Trauma Data Bank. Am J Surg 2006; 192:710–4. https://doi.org/10.1016/j.amjsurg.2006.08.031 PMID: 17161080

14. Ahmad R, Cherry RA, Lendel I, Mauger DT, Service SL, Texter LJ, et al. Increased hospital morbidity among trauma patients with diabetes mellitus compared with age- and injury severity score-matched control subjects. Arch Surg Chic Ill 1960 2007; 142:613–8. https://doi.org/10.1001/archsurg.142.7.613 PMID: 17638797

15. Machado-Aranda DA, Jakubos JL, Wahl WL, Cherry-Bukowiec JR, To KB, Park PK, et al. Reduction in Venous Thromboembolism Events: Trauma Performance Improvement and Loop Closure Through Participation in a State-Wide Quality Collaborative. J Am Coll Surg 2015; 221:661–8. https://doi.org/10.1016/j.jamcollsurg.2015.05.006 PMID: 26195250

16. Calland JF, Nathens AB, Young JS, Neal ML, Goble S, Abelson J, et al. The effect of dead-on-arrival and emergency department death classification on risk-adjusted performance in the American College of Surgeons Trauma Quality Improvement Program. J Trauma Acute Care Surg 2012; 73:1086–91; discussion 1091–1092. https://doi.org/10.1097/TA.0b013e31826fc7a0 PMID: 23117375

17. Wahl WL, Taddiono M, Maggio PM, Arbabi S, Hemmila MR. Mean glucose values predict trauma patient mortality. J Trauma 2008; 65:42–7; discussion 47–48. https://doi.org/10.1097/TA.0b013e318176c54e PMID: 18580507

18. Association AD. Economic Costs of Diabetes in the U.S. in 2012. Diabetes Care 2013; 36:1033–46. https://doi.org/10.2337/dc12-2625 PMID: 23468086

19. Warren DK, Shukla SJ, Olsen MA, Kollef MH, Hollenbeak CS, Cox MJ, et al. Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center. Crit Care Med 2003; 31:1312–7. https://doi.org/10.1097/01.CCM.0000063087.93157.06 PMID: 12771596

20. Hemmila MR, Jakubus JL, Maggio PM, Wahl WL, Dimick JB, Campbell DA, et al. Real money: complications and hospital costs in trauma patients. Surgery 2008; 144:307–16. https://doi.org/10.1016/j.surg.2008.05.003 PMID: 18656640

21. Heyland DK, Cook DJ, Griffith L, Keenan SP, Brun-Buisson C. The Attributable Morbidity and Mortality of Ventilator-Associated Pneumonia in the Critically Ill Patient. Am J Respir Crit Care Med 1999; 159:1249–56. https://doi.org/10.1164/ajrccm.159.4.9807050 PMID: 10194173

22. Arthur LE, Kizor RS, Selim AG, van Driel ML, Seoane L. Antibiotics for ventilator-associated pneumonia. Cochrane Database Syst Rev 2016; 10:CD004267. https://doi.org/10.1002/14651858.CD004267.pub4 PMID: 27763732

23. Cook DJ, Kollef MH. Risk Factors for ICU-Acquired Pneumonia. JAMA 1998; 279:1605–6. https://doi.org/10.1001/jama.279.20.1605 PMID: 9613699

24. Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Executive Summary: Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis Off Publ Infect Dis Soc Am 2016; 63:575–82. https://doi.org/10.1093/cid/ciw504 PMID: 27521441

25. Trevelin SC, Carlos D, Beretta M, da Silva JS, Cunha FQ. Diabetes Mellitus and Sepsis: A Challenging Association. Shock Augusta Ga 2016. https://doi.org/10.1097/SHK.0000000000000778 PMID: 27787406

26. Deng H-P, Chai J-K. The effects and mechanisms of insulin on systemic inflammatory response and immune cells in severe trauma, burn injury, and sepsis. Int Immunopharmacol 2009; 9:1251–9. https://doi.org/10.1016/j.intimp.2009.07.009 PMID: 19647101

27. Boyanova L, Mitov I. Antibiotic resistance rates in causative agents of infections in diabetic patients: rising concerns. Expert Rev Anti Infect Ther 2013; 11:411–20. https://doi.org/10.1586/ent.13.19 PMID: 23566150

28. Hemmila MR, Taddiono MA, Arbabi S, Maggio PM, Wahl WL. Intensive insulin therapy is associated with reduced infectious complications in burn patients. Surgery 2008; 144:629–35; discussion 635–637. https://doi.org/10.1016/j.surg.2008.07.001 PMID: 18847648

29. Read JL, Cheng EY. Intensive insulin therapy for acute hyperglycemia. AACN Adv Crit Care 2007; 18:200–12. https://doi.org/10.1097/01.AACN.0000269264.22041.1c PMID: 17473549

30. Van den Bergh G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001; 345:1359–67. https://doi.org/10.1056/NEJMoa011395 PMID: 11794168
31. Delano MJ, Ward PA. The immune system's role in sepsis progression, resolution, and long-term outcome. Immunol Rev 2016; 274:330–53. https://doi.org/10.1111/imr.12499 PMID: 27782333

32. Delano MJ, Ward PA. Sepsis-induced immune dysfunction: can immune therapies reduce mortality? J Clin Invest 2016; 126:23–31. https://doi.org/10.1172/JCI82224 PMID: 26727230